Scanning Medical Journals
No new significant updates or guidelines matching this topic were found today. We will check again soon.
Breslow Depth Analyzer
Melanoma Management Matrix
Depth Logic
Adjust the Breslow thickness and ulceration status to resolve surgical recommendations.
Verified
Last Review: 2026
| Feature | Breslow Depth | Clark Level |
|---|---|---|
| Definition | Vertical tumor thickness in millimeters from granular layer (or ulcer base) to deepest invasive cell | Anatomic level of invasion (I-V) based on dermal layers |
| Levels/Categories | Continuous variable (0.1 to 20+ mm), categorized into AJCC T categories (T1-T4) | 5 ordinal levels: I (intraepidermal), II (papillary dermis), III (papillary-reticular interface), IV (reticular dermis), V (subcutaneous fat) |
| Inter-observer reliability | High (0.85-0.95 correlation coefficient, precise measurement) | Low to moderate (kappa 0.45-0.65, subjective boundaries of dermal layers) |
| Prognostic power | Superior (single most important prognostic factor per AJCC) | Inferior (no longer used in AJCC 8th Edition for T staging, but may be reported for historical completeness) |
| Use in AJCC 8th Edition | Primary determinant of T category (T1-T4 based on thickness and ulceration) | Not used in formal staging (dropped after AJCC 5th Edition in 2001) |
| Correlation with SLNB positivity | Continuous: 5% (≤0.8 mm), 10-15% (0.8-1.0 mm), 15-25% (1.01-2.0 mm), 30-45% (2.01-4.0 mm), >50% (>4.0 mm) | Clark IV/ V higher risk than Clark II/III, but does not add independent prognostic information after adjusting for Breslow |
| Clinical utility (2024) | Essential for staging, margins, SLNB decision, and adjuvant therapy | Historical; rarely used in modern clinical decision-making except for T1a classification (≤0.8 mm AND no ulceration AND Clark level IV may upstage to T1b? Controversial; NCCN does not recommend) |
| T Category | Breslow Depth (mm) | Ulceration Status | Estimated 5-year Survival (Stage I-II) | SLNB Positivity Rate | Management Implications |
|---|---|---|---|---|---|
| Tis (in situ) | N/A (no invasion; melanoma confined to epidermis) | Not applicable | ~99-100% | <1% (rarely positive) | Wide local excision with 0.5-1.0 cm margins, no SLNB, no adjuvant therapy. Complete excision is curative. |
| T1a | ≤0.8 mm | No ulceration | ~99% (similar to Tis) | ~5-7% (low, but not zero) | WLE with 1.0 cm margins. SLNB may be considered if mitotic rate ≥1/mm², lymphovascular invasion, or patient young age (but NCCN: discussion for T1b only). Controversial; most guidelines do NOT recommend routine SLNB for T1a. |
| T1b | ≤1.0 mm | Yes (ulceration) OR 0.8-1.0 mm regardless of ulceration | ~97-98% | ~10-15% (higher if ulcerated) | WLE with 1.0 cm margins. SLNB recommended for discussion (NCCN: consider SLNB for T1b, especially if ulcerated or high mitotic rate). Adjuvant therapy not standard (unless SLNB positive). |
| T2a | 1.01 - 2.0 mm | No ulceration | ~93-96% | ~15-20% | WLE with 1.0-2.0 cm margins (1 cm acceptable, 2 cm preferred by some). SLNB indicated (NCCN Category 1 recommendation). If SLNB negative, observation. If SLNB positive, complete lymph node dissection or nodal observation (MSLT-II trial), consider adjuvant immunotherapy. |
| T2b | 1.01 - 2.0 mm | Yes (ulceration) | ~90-93% | ~25-30% | Same as T2a but higher risk; SLNB mandatory. Adjuvant therapy if SLNB positive. Consider baseline imaging (CXR, LDH) due to higher risk. |
| T3a | 2.01 - 4.0 mm | No ulceration | ~85-90% | ~30-40% | WLE with 2.0 cm margins. SLNB indicated (Category 1). Baseline imaging (CXR, LDH, CT chest/abdomen/pelvis if high-risk symptoms or for clinical trial). Adjuvant therapy if SLNB positive. |
| T3b | 2.01 - 4.0 mm | Yes (ulceration) | ~75-85% | ~40-50% | Same as T3a but higher risk. Baseline imaging recommended (CT or PET-CT) even if SLNB negative (due to higher distant metastasis risk). |
| T4a | >4.0 mm | No ulceration | ~70-80% | ~50-65% | WLE with 2.0 cm margins. SLNB indicated. Baseline imaging required (CT chest/abdomen/pelvis or PET-CT). Consider adjuvant immunotherapy even if SLNB negative? NCCN: For T4 (≥4 mm), consider adjuvant therapy discussion if high risk (ulcerated, positive SLNB, multiple primaries). |
| T4b | >4.0 mm | Yes (ulceration) | ~50-60% | ~65-75% | Same as T4a. Very high risk. SLNB mandatory. Baseline imaging required. Strongly consider adjuvant immunotherapy (anti-PD-1, e.g., pembrolizumab, nivolumab) even if SLNB negative (based on extrapolation from stage III trials and high recurrence risk). Clinical trial if available. |
Last Comprehensive Review: 2026
